Biomarkers of Inflammatory Bowel Disease

Yi Fengming and Wu Jianbing

*Department of Oncology, Second Affiliated Hospital of Nanchang University, Minde Road 1, Nanchang, Jiangxi 330006, China*

Correspondence should be addressed to Wu Jianbing; wujianbing1234@163.com

Received 10 April 2014; Accepted 6 May 2014; Published 19 May 2014

Academic Editor: Claudio Letizia

Inflammatory bowel disease (IBD) is a chronic disease mostly involved with intestine with unknown etiology. Diagnosis, evaluation of severity, and prognosis are still present as challenges for physicians. An ideal biomarker with the characters such as simple, easy to perform, noninvasive or microinvasive, cheap, rapid, and reproducible is helpful for patients and clinicians. Currently biomarkers applied in clinic include CRP, ESR, pANCA, ASCA, and fecal calprotectin. However, they are far from ideal. Lots of studies are focused on seeking for ideal biomarker for IBD. Herein, the paper reviewed recent researches on biomarkers of IBD to get advances of biomarkers in inflammatory bowel disease.

1. Introduction

Inflammatory bowel disease (IBD) includes Crohn’s disease (CD) and ulcerative colitis (UC) with unknown etiology. Physicians get the diagnosis of IBD usually based on the combination of clinical features, laboratory tests, radiology, endoscopy, and pathology. Diagnosis, evaluation of severity, and prognosis are still present as challenges for clinicians. Laboratory biomarkers are noninvasive or microinvasive, objective, and rapid and cost less than other techniques, which relieve physiological and financial burden for patients. An ideal biomarker for IBD should be simple, easy to perform, noninvasive or microinvasive, cheap, rapid, and reproducible [1]. Unfortunately, there are no biomarker satisfying these characteristics. Herein, the authors search “Web of Science” and “PubMed” by key words “inflammatory bowel disease,” “ulcerative colitis,” “Crohn’s disease,” “marker,” and “biomarker” to get advances of biomarkers in inflammatory bowel disease.

2. Markers Related to Genetic Predisposition

Family history is a risk factor for developing IBD, with a peak incidence in early adult life, although individuals of any age can be affected [2]. But family history does not affect the severity of CD [3]. Various candidate genes for IBD have been discovered through genome-wide association studies (GWAS) or candidate gene approaches, but only three genetic polymorphisms related to NOD2, IL23/17, and autophagy have been well established for a direct pathogenetic role. Furthermore, genetic variants associated with IBD can vary in frequency depending on the cohort ethnicity; it changes with different racial and ethnic groups.

2.1. NOD2.

A large number of identified susceptibility loci have been explored in both CD and UC [2]. NOD2, the only one contributed to CD risk alone [4]. Homozygous or compound heterozygous mutations in NOD2 are associated with the reduced activation of transcription factor nuclear factor-κB (NF-κB) [5].

The most common mutation occurs in Caucasians other than eastern Asians. Disease predisposing mutations of NOD2 are present in Turkish and Iranian patients, but they are absent in Japanese, Han Chinese, Indian, and Malaysian patients with CD [6]. The variants within NOD2 are mainly predisposed to ileal, stenosing, and familial CD [7]. So sequencing for NOD2 variants is quite important for Caucasians as it could contribute to CD risk, and it is controversial for Asians.

2.2. Autophagy Genes.

GWAS for CD shows the genes regulating autophagy, including autophagy 16-like 1 (ATG16L1), immunity-related guanosine triphosphatase M (IRGM), and leucine-rich repeat kinase 2 (LRRK2) genes, which are associated with CD risk [8, 9].
For ATG16LI, studies show that 12 previously CD-associated SNPs in West are not found in Asians studied [10]. Moreover, 8 SNPs of the IRGM gene did not show relation with CD and UC in a Japanese study [11]. However, a Korean study shows that IRGM SNP rs10065172 is significantly associated with CD susceptibility and also find a protective relationship between the SNP rs72553867 and the CD susceptibility [12]. So it is confused with different races, and more researches are needed to confirm it.

2.3. IL23R. Several common variants in the IL-23 receptor gene (IL23R) are reported to be clearly associated with both CD and UC susceptibility [10]. But in east Asia, IL23R variants does not show any association with CD [13–15]. IL23R is a CD susceptibility gene, but different IL23R variants are likely to carry variable disease-modifying effects in different populations.

The gene also affects the strategies of treatment. A research in Germany shows that homozygous carriers of IBD risk-increasing IL23R variants are more apt to respond to anti-TNF than homozygous carriers of IBD risk-decreasing IL23R variants [16].

3. Markers Related to Disease Type

IBD is an immune-related disease, some immune-associated markers are also explored for this disease. The differentiation of UC and CD is also quite difficult for physicians especially when the clinical, endoscopic, and pathologic features are not typical or confused. However, some markers could help to resolve part of them.

3.1. Antineutrophil Cytoplasmic Antibodies. Antineutrophil cytoplasmic antibodies (ANCA) are antibodies for granules of neutrophil cytoplasm; it is first reported in UC patients in 1990 [17]. Atypical perinuclear ANCA (pANCA) is DNase sensitive [18]; it increases significantly in UC [19]. A prospective followup study recruiting 197 IBD-unclassified (IBD-U) demonstrates that 64% UC patients are anti-Saccharomyces cerevisiae antibody (ASCA)−/pANCA+ [20]. Another nation-based survey shows that the positive rate of pANCA is 55% in UC, 48% in rheumatoid arthritis, and 32% in healthy people [21]. We recruit 152 UC, 54 CD, and 60 IBD-U demonstrating that the sensitivity and specificity of pANCA are 43.3% and 96.3% separately when compared to healthy controls (HC) [22].

3.2. Anti-Saccharomyces cerevisiae Antibodies. ASCAs are antibodies for mannan in cell wall of Saccharomyces cerevisiae (S. cerevisiae); it is homologous to cell wall of enterobacteria [23]. Mallant-Hent et al. find that ASCA does not exist in membrane of S. cerevisiae, which indicates that ASCAs have no relationship with mucosa exposure of S. cerevisiae [24]. ASCAs have best sensitivity and specificity, it could reach up to 31%–45% and 90%–100%, respectively, when compared with other antibodies such as anti-Escherichia coli outer-membrane porin C (anti-OmpC), anti-chitobioside carbohydrate IgA antibodies (ACAs), anti-laminaribioside carbohydrate IgG antibodies (ALCs), anti-mannobioside carbohydrate IgG antibodies (AMCs), anti-chitin (anti-C), and anti-laminarin (anti-L) [19]. A prospective long-term followup study including 197 IBD-U shows that 80% CD are ASCA+/pANCA− [20]. The sensitivity and specificity for ASCA in CD are 46.3% and 96.3%, respectively [22]. Another research admits 15 idiopathic ocular inflammations without IBD but with IBD family history; pANCA increases in 8 patients, however it increases in just 3 healthy controls (P = 0.004) [25].

Apart from pANCAs and ASCAs, other serological antibodies such as anti-OmpC, ALCAs, ACCAs, AMCs, anti-L, and anti-C and pancreatic autoantibodies (PAB) also contribute to diagnosis and differential diagnosis of IBD and other diseases [19, 26–28].

4. Markers Related to Inflammation or Disease Activity

Various markers have been proposed to objectively evaluate disease activity or inflammation, but sensitivity and specificity have been a concern for each. A combination of biomarkers may be the most useful for prediction or confirmation of clinical disease activity and endoscopically visible inflammation.

4.1. C-Reactive Protein and Hypersensitive C-Reactive Protein. C-reactive protein (CRP) is considered as one of the most important protein in acute inflammation; it consist of 5 components [29]. It maintains low level in circulation secreted by hepatocytes in healthy individuals (<1 mg/L), but it sharply increases even reaching up to 350–400 mg/L when acute inflammation which is induced by interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and IL-1β. The level 10–40 mg/L indicates chronic inflammation or virus infection. Half-life of CRP is quite short (19 h); it increases rapidly and decreases sharply in acute inflammation. It responds differently in UC and CD; CD is correlated with CRP significantly but UC is not [30, 31]; the mechanism is still unknown. Hypersensitive C-reactive protein (Hs-CRP) and β2-microglobulin correlated with histology scores of UC [32]. Hs-CRP is useless in evaluation of disease severity and corticosteroids therapy of pediatric IBD with normal level of CRP [33].

4.2. Erythrocyte Sedimentation Rate. Erythrocyte sedimentation rate (ESR) indicates migration speed of red blood cells in plasma; it varies with concentration of plasma and the size of erythrocyte. It is significantly altered when in patients with anemia, globulism, or Mediterranean anemia [34]. Time to peak and decline is delayed for ESR when compared with CRP.

4.3. Platelets Count. Platelets (PLT) increase in patients with IBD, which contribute to high-coagulated state of IBD, such as the formation of microthrombus [35–37]. Moreover, reticulated platelet levels increase significantly in patients with ulcerative colitis [38].
4.4. Mean Platelet Volume. Mean platelet volume (MPV) indicates average size of platelet; it could reflect the rate of platelet stimulation and production. Kapsoritakis et al. [39] find out that MPV decreased significantly in active-IBD, and it negatively correlated with some markers of inflammation, such as white blood cell (WBC), CRP, and ESR. However, another research does not show any relationship between this parameter and disease activity [40]. The decline of MPV may be related with disturbance of thrombus formation when inflammation occurs [39].

4.5. Red blood Cell Distribution. Red blood cell distribution (RDW) reflects the size and variability of erythrocytes in peripheral circulation, it is usually detected in blood regular test in hospital [41]. A study including 221 IBD (120 UC and 101 CD) shows that CRP, ESR, and RDW increase in IBD ($P < 0.05$); multivariate analysis shows that RDW has the best prediction when evaluated disease activity for CD patients with nonanemia. When the cutoff of RDW was 13.8, the sensitivity and specificity are 76% and 86% for nonanemic UC separately; it could reach up to 82% and 83% for nonanemia CD when cutoff was 14.1 [42]. Another study demonstrates reticulocyte distribution width (RDWR) and red blood cell size (RSF) have significant diagnostic value for IBD with iron-deficiency anemia; it could reflect disease activity and anemia for IBD patients [43].

4.6. Fecal Calprotectin. Fecal calprotectin is a protein in neutrophil granulocytes and macrophages; it consists of S100A8 and S100A9 and is first found and described in 1980 [44]. It is stable and well-distributed in feces which make it reflect the entire state of the feces when we detect a part of it [45]. Calprotectin is considered as one type of damage associated with molecular pattern protein (DAMP). It is released by activated innate immunity cells when cell stresses and damages, which also reflect the process of inflammation [46].

More and more studies focus on fecal calprotectin in IBD and confirm its value in diagnosis, disease activity evaluation, effect evaluation, and relapse monitor [46]. A prospective cohort study demonstrates that the sensitivity and specificity of CD are 100% and 97% (cutoff 30 mg/L) when compared to irritable bowel syndrome (IBS) [47].

Schoepfer et al. detect fecal calprotectin and IBD-related antibodies; they show that the accuracy of fecal calprotectin is 89% when compared to IBS (sensitivity and specificity were 83% and 100%, resp.); the accuracy is just 91% when combined with ANCA or ASCA [48].

A meta-analysis including 30 prospective studies confirms that the sensitivity and specificity of fecal calprotectin could reach up to 95% and 91%, respectively; the accuracy in children is higher than in adults. Moreover, fecal calprotectin is better than CRP, ESR, ASCA, pANCA, and OmpC [49]. Another meta-analysis shows that fecal calprotectin could reduce 67% of endoscopy in adult, but it also could delay the treatment of 6% of patients as its false negative [50]. Studies also find fecal calprotectin level is significantly higher in active colonic CD than in active ileal CD [51]; left-sided and distal UC are higher than pancolonic UC [52]; fecal calprotectin also could evaluate the effect of treatment [53]. Calprotectin decreases significantly after IFX treatment for 12 weeks, and it correlated with endoscopic index of severity (CDEIS) ($r = 0.561$, $P = 0.03$) [54]. Røseth et al. show that fecal calprotectin level correlated with endoscopic mucosal healing [55]. A meta-analysis focusing on fecal calprotectin in IBD relapse shows that the sensitivity and specificity when predicting the relapse are 78% and 73%, separately [56]. A study recruiting 60 newly diagnosed CD patients without treatment finds there is no difference of calprotectin level between small intestine involved only and small intestine and colon involved; it is not correlated with pediatric CD activity index (CDAI), but it decreases as other markers such as ESR or CRP [57]. Calprotectin in 1/3 of the children decreases significantly when treated with IFX for pediatric IBD, which indicates that it gets mucosal healing [58]. A study demonstrates that calprotectin level >100 ng/g could implicate positive findings in capsule endoscopy; there is no need of capsule endoscopy when <100 ng/g [59]. The use of fecal calprotectin would improve diagnostic yield in patients with abdominal complaints in addition to European Panel on the Appropriateness of Gastrointestinal Endoscopy (EPAGE) criteria [60].

A systematic review conclude that, for distinguishing between IBD and IBS in adults, these gave pooled sensitivity of 93% and specificity of 94% at fecal calprotectin cutoff level of 50 μg/g. Sensitivities at that cutoff ranged from 83% to 100% and specificities from 60% to 100%. For distinguishing between IBD and non-IBD in pediatric populations with ELISA tests, sensitivities ranged from 95% to 100% at cutoff of 50 μg/g and specificities of 44%–93%. Fecal calprotectin can be a highly sensitive way of detecting IBD, although there are inevitably tradeoffs between sensitivity and specificity, with some false positives (IBS with positive calprotectin), if a low calprotectin cutoff is used. In most cases, a negative calprotectin rules out IBD, thereby sparing most people with IBS from having to have invasive investigations, such as colonoscopy [61].

National Institute for Health and Care Excellence (NICE) guideline for fecal calprotectin diagnostic tests for inflammatory bowel disease gives recommendations for the differential diagnosis of inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS) in adults or children, and it is a useful screening test to triage referrals to gastroenterology for investigation of chronic diarrhea, without rectal bleeding, in patients under the age of 60 years [62].

4.7. Fecal Lactoferrin. Lactoferrin is an iron-binding protein; it covers most mucosal surface and interacts with exocrine organs or substances including parotid, tears, vaginal discharge, articular synovia, and latex [63–65]. It is a component of neutrophil granulocytes and activated in acute inflammation [65]. Fecal lactoferrin increases significantly as infiltration of neutrophils in intestinal tracts [66]. It is stable for 5 days in feces whenever repeating freeze thawing [67].

Sugi et al. find that lactoferrin could reflect inflammation of intestine [68]. The diagnostic rate of lactoferrin for IBD could reach up to 80% when compared with IBD, which is similar to fecal calprotectin and better than CRP (64%)
The sensitivity and specificity are 86% and 100% when compared with HC and IBS, and there is a significant difference between active-IBD and inactive-IBD [65], but a study does not find any difference between active-CD and inactive-CD [70]. Fecal lactoferrin also associated with disease activity and ESR pediatric IBD patients [67].

4.8. Fecal Neopterin. Both fecal calprotectin and fecal neopterin concentrations correlated with endoscopic scores in UC ($r = 0.75$ and $r = 0.72$, resp.; $P < 0.0001$ for both) better than in CD ($r = 0.53$ and $r = 0.47$, resp.; $P < 0.0001$ for both). Using cutoffs of 250 $\mu$g/g for fecal calprotectin and 200 pmol/g for fecal neopterin, both fecal markers have similar overall accuracies to predict endoscopic activity in patients with CD (74%) and a higher accuracies in patients with UC (88% and 90%, resp.), whereas accuracies of C-reactive protein are slightly lower in patients with CD and UC [71]. Another study recruiting 70 CD and 52 UC shows fecal neopterin increases just in feaces other than in serum and urine [72].

4.9. S100A12. Scholars consider S100A12 as a novel biomarker which could meet these characters: high sensitivity and specificity, easy to take and detect, cheap, and of good compliance [73]. S100A12 is a member of S100 calcium binding protein family [74]; it is activated extracellular similar to S100A8 and S100A9. S100A12 participates a lot in proinflammation processes; it stimulates proinflammation mediators by NF-κB or other similar pathways [75]. It could be stable for 7 days in room temperature and increases in inflammatory diseases such as arthritis and Kawasaki disease [76, 77]. It also correlated with the prognosis of severe respiratory reaction in premature children [78]. Early diagnosis and inflammation control seem to be quite important for pediatrics; it could avoid long-term or short-term complications. Uncontrolled inflammation usually correlated with loss of weight, restriction of height, and delay of adolescence [79]. Fecal S100A12 correlated with inflammatory biomarkers and pediatric CD activity index (pCDAI) [80]. Fecal S100A12 decreases gradually when the children got clinical remission [80]. However, S100A12 increases significantly in severe acute pediatric UC patients, but it does not correlated with response of treatment [81].

The sensitivity and specificity of fecal S100A12 could reach up to 86% and 96% respectively, it is higher than fecal calprotectin [82]. Another study also shows S100A12 is better than calprotectin when compared with HC; its sensitivities in CD and UC are 81% and 91% separately, and the specificity is 100% in both groups. Fecal S100A12 is also elevated in bacterial enteritis but not in viral gastroenteritis. Fecal S100A12 correlated better with intestinal inflammation than fecal calprotectin or other biomarkers [82].

Foell et al. shows that S100A12 upregulated in serum of UC and CD, and it correlated with disease activity [83]. Studies also demonstrate the level of fecal S100A12 decreases as anti-inflammation treatment, suggesting that this marker could reflect the response of drug treatment. S100A12 could predict mucosal healing and recurrence of disease; the method of evaluation of mucosal healing currently is endoscopic and histopathological examination; the invasive, and expensive examinations could be replaced by noninvasive detection [73]. However, more studies need to confirm S100A12 in IBD evaluation.

A study aims to investigate the role of calprotectin and S100A12 in predicting inflammatory lesions of small bowel in patients undergoing wireless capsule endoscopy (WCE). The result shows that fecal calprotectin is significantly higher in CD patients compared with those with normal WCE or other abnormalities ($P = 0.008$), whereas fecal S100A12 does not differ between the groups. When detecting inflammatory small bowel lesions, sensitivity, specificity, positive predictive value, and negative predictive value for fecal calprotectin (cutoff 50 $\mu$g/g), they are 59%, 71%, 42%, and 83%, and for S100A12 (cutoff 0.06 $\mu$g/g), these are 59%, 66%, 38%, and 82% [84]. A review concludes that S100A12 is valuable in diagnosis, distinguish, recurrence monitor, and treatment of IBD [85].

4.10. MicroRNAs. MicroRNAs (miRNAs) are small noncod-ed single-stranded RNAs (approximately 18–24 nucleotides); they are negatively regulatory molecules for genes. The unbalance of miRNAs could emerge in physiopathologic processes of multiple diseases, such as aloplasia, arrhythmia, schizophrenia, cancer, and immune-related diseases [86]. The effect of miRNAs in innate immunity and adaptive immunity such as immune-mediated psoriasis, rheumatoid arthritis, asthma, and systemic lupus erythematosus (SLE) has been confirmed by studies [87]. Some serological miRNAs upregulated or downregulated in IBD [88].

4.11. Adenosine Deaminase. There is significant increase of adenosine deaminase (ADA) in active CD patients when compared with HC and patients in remission, and ADA correlated with CRP ($r = 0.516$), which may be a new biomarker for CD activity [89].

4.12. Lipopolysaccharide-Binding Protein and CD14. A research recruits 214 CD and 110 HC, to detect lipopoly saccharide-binding protein (LBP), CD14, hs-CRP, ASCA IgG/IgA, anti-OMP IgA, and pANCA. Serological LBP increases and soluble CD14 decreases significantly. In addition, LBP and CD14 correlated with hs-CRP; the accuracy of evaluation of active CD equals to hs-CRP [90].

4.13. Abnormal Lectin-Based IgG Glycosylation. Serological IgG in IBD has higher affinity for lectin compared with HC. A study takes in 410 IBD (include 290 Japanese and 161 Americans) and HC; abnormal lectin-based IgG glycosylation increases significantly in CD when compared with HC; it correlated with disease activity and has higher specificity than CRP when it combines with ASCA [91].

4.14. Mopterin. Mopterin is a component of piperazine-[2,3-d]-pyrimidine, which is a metabolic product of cyclic guanosine monophosphate [92]. Mopterin is released by $T$ lymphocytes and macrophages stimulated by $\gamma$-interferon [93]. Some researchers find that mopterin increases in urine
and serum of UC and CD [92, 94–97]. Another study shows tumor necrosis factor-\( \alpha \) (TNF-\( \alpha \)) correlated with serological mopterin \( (r = 0.73, P < 0.0001) \) [98]. Serological mopterin also correlated with ESR [97]. However, a study including 70 CD and 52 UC does not find any changes of mopterin in serum and urine but rather in stool [72].

4.15. Soluble ST2. ST2 is a member of IL-1R superfamily; it is consists of 2 parts (ST2L and sST2) and coded by 2nd chromosome [99]. A study recruits 110 IBD (82 UC and 26CD) and healthy controls shows that serological sST2 is higher in active-UC when compared with nonactive ones; the sensitivity, specificity, and accuracy are 83.3%, 83.3%, and 83.3%, respectively. Moreover, it significantly correlated with endoscopic activity scores [100].

4.16. Nitric Oxide. A study (30 UC, 30 CD, and 30 HC) demonstrates that there are significantly different concentrations of nitric oxide (NO) between three groups. With a cutoff level of 17.39 \( \mu \)mol/L NO has a sensitivity of 100% and a specificity of 100% in distinguishing active and inactive UC patients. With cutoff value of 14.01 \( \mu \)mol/L serum NO level has a sensitivity of 88% and a specificity of 69% in distinguishing patients with active CD and inactive CD [101].

Exhaled nitric oxide (NO) could indicate Crohn’s disease involved in lungs; a study shows that exhaled NO increases significantly in CD compared to controls [102].

4.17. Soluble Triggering Receptor Expressed on Myeloid Cells-1. Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) notably correlated with endoscopic activity score, which indicates it might be a biomarker to evaluate endoscopic activity [103].

4.18. Substance P. Serum substance P level sharply increases in 61 UC and 66 CD when compared with HC \( (P < 0.01) \); it correlated with disease activity in UC \( (P = 0.014) \) and it decreases immediately when get endoscopic and clinical remission \( (P = 0.025) \). However, there is no difference between active CD and inactive CD, it usually increases in inactive stricture or penetrare CD [104].

4.19. Activated Thrombin Activatable Fibrinolysis Inhibitor. Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is considered to be related with pathogenesis and progress of IBD. Plasma TAFIa increases significantly in CD, and it correlated with WBC, CRP, fibrinogen, and platelet, which indicates it might be a potential IBD biomarker [105].

4.20. Quantitative Fecal Immunochemical Test. Quantitative fecal immunochemical tests (FITs) could detect fecal blood rapidly. A study consists of 152 UC demonstrates that the sensitivity and specificity of FIT could reach up to 92% and 71% when cutoff <100 ng/mL; FIT also correlated with Mayo scores [106].

4.21. Chitinase 3-Like-1. Chitinase 3-like-1 (CHI3L1/YKL-40) is a protein excreted by endotheliocytes and macrophages in intestine. The sensitivity and specificity of fecal CHI3L1 could reach up to 84.7% and 88.9% when cutoff was 13.7 ng/g in active-IBD [107].

4.22. Angiogenin. Angiogenin increases significantly in IBD when compared with HC. Moreover it shows a sharply decrease of angiogenin when treated IBD patients with aminosalicylic acid (ASA), which indicates that angiogenesis is unbalance in IBD patients [108].

4.23. Mucosal Indoleamine 2,3 Dioxygenase-1. The activity of mucosal indoleamine 2,3 dioxygenase-1 (IDO1) is quite important in IBD diagnosis [109].

4.24. Mucosal Cytokine. Higher levels of IL-17A and IFN-\( \gamma \) are significantly correlated with remission after three IFX infusions \( (OR = 5.4, P = 0.013 \) and \( OR = 5.5, P = 0.011, \) resp.). IL-17A and IFN-\( \gamma \) mRNA expression showed positive correlation. Th2 and Treg-related mediators do not significantly associated with clinical outcome but are expressed at higher levels in UC patients when compared with the controls. High expression of Th1- and Th17-related cytokines could potentially predict a favorable outcome of IFX induction therapy in the mucosa of UC patients. Th2 and Treg-related mediators do not appear to be useful as predictive markers [110].

Mucosa-related biomarkers such as mucosal CD11c+ [III], cytokines and chemotactic factors, adhesion molecules, etc., are far from being ideal biomarkers [112].

4.25. Urine Neopterin. Neopterin in urine is used to distinguish active state and nonactive ones [92]. However, another study does not find any change for urine neopterin in different state of the disease [72].

Others such as soluble intercellular adhesion molecule-1, D-lactate, diamine oxidase, Pseudomonas fluorescens CD-related protein, OmpC, and CBir1 flagellin also correlated with IBD [113–115]. Dipeptidyl peptidase-4 (DP4) decreases significantly in CD which also might be a potential biomarker [116].

5. Markers Related to Drug Metabolism

Drugs for inflammatory bowel disease include aminosalicylic acid, corticosteroids, immunosuppressant, and anti-TNF agents. However, the reaction rate for patients with IBD is not ideal. Some markers are proposed to monitor the effect of the drugs.

5.1. Antibodies toward Infliximab. As biological agents are widely used in IBD, effect-monitoring of biological agents seems to be quite important. Serological antibodies to infliximab (ATIs) usually affect the treatment of infliximab (IFX). A meta-analysis collecting 13 studies including 1378 IBD patients shows the risk ratio (RR) of patients with ATIs failed treatment was 3.2 (95% CI: 2.0–4.9, \( P < 0.0001 \)) when compared with non-ATIs or low-ATIs. Although there exists a bias in this study, the research recently shows ATIs concentration significantly correlated with the effect of treatment, so the concentration of ATIs seems to be quite
important for patients with IFX [117, 118]. Furthermore, the antibodies to F(ab’2) exist in 67% ATI-positive patients; it is immunogenicity of ATI, but scholars declare ATIs are still more important than F(ab’2) when there is effect-monitoring of IFX in IBD [119].

pANCA seems to be valuable for predicting response to anti-TNF, as negative status of pANCA is associated with early response to anti-TNF drugs [16]. Th1- and Th17-related cytokines could potentially predict a favorable outcome of IFX induction therapy in the mucosa of UC patients. Th2 and Treg-related mediators do not appear to be useful as predictive markers [110].

5.2. Thiopurine Methyltransferase and 6-Thioguanine Nucleotide. The activity of thiopurine methyltransferase (TPMT) and the concentration of 6-thioguanine nucleotide (6TGN) are considered to be related with the treatment of thioguanine. However, recent study does not find any relationship between them [120].

5.3. Urine Salicylate Level. A study including 93 patients with UC taking mesalamine maintenance therapy prospectively enrolled from the clinics. Random urine salicylate levels (by colorimetry) were highly correlated with urine 5-ASA metabolite levels (by mass spectrometry; \( R^2 = 0.9 \)). A random urine salicylate level above 15 mg/dL distinguishes patients who have recently taken mesalamine from controls (area under the curve value 0.9, sensitivity 95%, and specificity 77%) [121].

5.4. Genes. Some studies also found the association between genetic factors and response to treatment; they affect the strategies of treatment. Multidrug resistant 1 (MDRI) polymorphisms is associated with corticosteroid refractoriness in CD and UC, and it is also correlated with a higher risk of cyclosporine failure in patients with steroid-resistant UC [122, 123]. A research in Germany shows homozygous carriers of IBD risk-increasing IL23R variants are more apt to respond to anti-TNF than homozygous carriers of IBD risk-decreasing IL23R variants [16]. Another study such as apoptosis genes polymorphisms predict response to infliximab therapy in luminal and fistulizing Crohn's disease [124].

6. Markers Related to Neoplastic Transformation

Ulcerative colitis is considered to be a precancerous lesion; it could progress to colorectal cancer (CRC) as the disease duration extends. So the surveillance for it before canceration should be emphasized.

6.1. M2-Pyruvate Kinase. M2-pyruvate kinase (M2PK) often exists in undifferentiated or proliferous tissues and could be detected in serum and feces [125]. It increases in multiple traumas, chronic cardiac failure, tumors, and poutisitis [126–129], some scholars also find the relationship between M2PK and IBD [130]. The enzyme was stable in room temperature and could be detected by enzyme linked immunosorbent assay (ELISA) [129]. M2PK increases significantly in UC, CD, and CRC when compared with IBS, and it is lineararily correlated with calprotectin. It might be a potential marker for screening CRC in IBD patients, and more researches need to confirm it.

6.2. miRNAs. Studies found miRNAs up-regulated or down-regulated in mucosa of different sites [131, 132]. PDCD4/miR-21 was often un-balance in precancerous changes or intraepithelial neoplasias of mucosa in IBD. miR-21 increases but PDCD4 decreases may indicate they could be biomarkers of IBD canceration [133]. miRNAs increases significantly in mucosa of IBD by micro-array analysis and real-time polymerase chain reaction [134].

There is no literature on fecal miRNAs and IBD, but fecal miRNA-92a was confirmed to be predictive in CRC and adenomatous polyp; the sensitivities were 71.6% and 56.1%, respectively; specificities were both 73.3% [135].

6.3. Mucosal CHI3L1. Mucosa CHI3L1 is highly expressed in intraepithelial neoplasias mucosa of UC cryptoeithelium and increases when developed to CRC. So it might be a biomarker to monitor malignant degeneration of UC [136].

7. Conclusions

Studies on IBD biomarkers were subdivided into 5 parts; however, invasive, expensive, physical, and mental burden for mucosa or tissue restricts its applications. Currently biomarkers applied in clinic include CRP, ESR, pANCA, ASCA, and fecal calprotectin; other biomarkers still need to be confirmed in large clinic research. These biomarkers bring convenience for patients and clinicians, but biomarkers are still far from ideal.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] S. Vermeire, G. van Assche, and P. Rutgeerts, “Laboratory markers in IBD: useful, magic, or unnecessary toys?” Gut, vol. 55, no. 3, pp. 426–431, 2006.
[2] B. Khor, A. Gardet, and R. J. Xavier, “Genetics and pathogenesis of inflammatory bowel disease,” Nature, vol. 474, no. 7351, pp. 307–317, 2011.
[3] F. Carbonnel, G. Macaigne, L. Beaugerie, J. P. Gendre, and J. Cosnes, “Crohn’s disease severity in familial and sporadic cases,” Gut, vol. 44, no. 1, pp. 91–95, 1999.
[4] J. H. Cho and S. R. Brant, “Recent insights into the genetics of inflammatory bowel disease,” Gastroenterology, vol. 140, no. 6, pp. 1704–1712, 2011.
[5] Y. Ogura, D. K. Bonen, N. Inohara et al., “A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease,” Nature, vol. 411, no. 6837, pp. 605–606, 2001.
Disease Markers

[6] S. C. Ng, K. K. Tsoi, M. A. Kamm et al., "Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis," Inflammatory Bowel Diseases, vol. 18, no. 6, pp. 1164–1176, 2012.

[7] M. Economou, T. A. Trikalinos, K. T. Loizou, E. V. Tsianos, and J. P. A. Ioannidis, "Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a meta-analysis," The American Journal of Gastroenterology, vol. 99, no. 12, pp. 2393–2404, 2004.

[8] J. H. Cheon, "Genetics of inflammatory bowel diseases: a comparison between Western and Eastern perspectives," Journal of Gastroenterology and Hepatology, vol. 28, no. 2, pp. 220–226, 2013.

[9] C. M. Moon, D. J. Shin, S. W. Kim et al., "Associations between genetic variants in the IRGM gene and inflammatory bowel diseases in the Korean population," Inflammatory Bowel Diseases, vol. 19, no. 1, pp. 106–114, 2013.

[10] K. Yamazaki, Y. Onouchi, M. Takazoe, M. Kubo, Y. Nakamura, and A. Hata, "Association analysis of genetic variants in IL23R, ATG16L1 and 5p13.1 loci with Crohn's disease in Japanese patients," Journal of Human Genetics, vol. 52, no. 7, pp. 575–583, 2007.

[11] M. J. Prescott, K. M. Dominy, M. Kubo et al., "Independent and population-specific association of risk variants at the IRGM locus with Crohn's disease," Human Molecular Genetics, vol. 19, no. 9, Article ID ddd041, pp. 1828–1839, 2010.

[12] C. M. Moon, D. J. Shin, M. D. Kim et al., "Associations between genetic variants in the IRGM gene and inflammatory bowel diseases in the Korean population," Inflammatory Bowel Diseases, vol. 15, no. 9, pp. 1385–1390, 2009.

[13] M. Nooij, W. C. de Bock, R. M. Festen et al., "Contribution of SLE, ATG16L1 and 5p13.1 loci with Crohn's disease in Japanese and A. Hata, "Association analysis of genetic variants in IL23R, ATG16L1 and 5p13.1 loci with Crohn's disease in Japanese patients," Journal of Human Genetics, vol. 52, no. 7, pp. 575–583, 2007.

[14] S.-K. Yang, M. Park, J. Lim et al., "Contribution of IL23R but not ATG16L1 to Crohn's disease susceptibility in Koreans," Inflammatory Bowel Diseases, vol. 15, no. 9, pp. 1385–1390, 2009.

[15] C. Bin, Z. Zhirong, W. Xiaolin et al., "Contribution of SLE, ATG16L1 and 5p13.1 loci with Crohn's disease in Japanese patients," Journal of Human Genetics, vol. 52, no. 7, pp. 575–583, 2007.

[16] M. J. Prescott, K. M. Dominy, M. Kubo et al., "Independent and population-specific association of risk variants at the IRGM locus with Crohn's disease," Human Molecular Genetics, vol. 19, no. 9, Article ID ddd041, pp. 1828–1839, 2010.

[17] C. M. Moon, D. J. Shin, S. W. Kim et al., "Associations between genetic variants in the IRGM gene and inflammatory bowel diseases in the Korean population," Inflammatory Bowel Diseases, vol. 19, no. 1, pp. 106–114, 2013.

[18] K. Yamazaki, Y. Onouchi, M. Takazoe, M. Kubo, Y. Nakamura, and A. Hata, "Association analysis of genetic variants in IL23R, ATG16L1 and 5p13.1 loci with Crohn's disease in Japanese patients," Journal of Human Genetics, vol. 52, no. 7, pp. 575–583, 2007.

[19] S. C. Ng, K. K. Tsoi, M. A. Kamm et al., "Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis," Inflammatory Bowel Diseases, vol. 18, no. 6, pp. 1164–1176, 2012.

[20] M. Economou, T. A. Trikalinos, K. T. Loizou, E. V. Tsianos, and J. P. A. Ioannidis, "Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a meta-analysis," The American Journal of Gastroenterology, vol. 99, no. 12, pp. 2393–2404, 2004.

[21] J. H. Cheon, "Genetics of inflammatory bowel diseases: a comparison between Western and Eastern perspectives," Journal of Gastroenterology and Hepatology, vol. 28, no. 2, pp. 220–226, 2013.

[22] M. J. Prescott, K. M. Dominy, M. Kubo et al., "Independent and population-specific association of risk variants at the IRGM locus with Crohn's disease," Human Molecular Genetics, vol. 19, no. 9, Article ID ddd041, pp. 1828–1839, 2010.

[23] C. M. Moon, D. J. Shin, S. W. Kim et al., "Associations between genetic variants in the IRGM gene and inflammatory bowel diseases in the Korean population," Inflammatory Bowel Diseases, vol. 19, no. 1, pp. 106–114, 2013.

[24] K. Yamazaki, Y. Onouchi, M. Takazoe, M. Kubo, Y. Nakamura, and A. Hata, "Association analysis of genetic variants in IL23R, ATG16L1 and 5p13.1 loci with Crohn's disease in Japanese patients," Journal of Human Genetics, vol. 52, no. 7, pp. 575–583, 2007.

[25] S.-K. Yang, M. Park, J. Lim et al., "Contribution of IL23R but not ATG16L1 to Crohn's disease susceptibility in Koreans," Inflammatory Bowel Diseases, vol. 15, no. 9, pp. 1385–1390, 2009.

[26] C. Bin, Z. Zhirong, W. Xiaolin et al., "Contribution of SLE, ATG16L1 and 5p13.1 loci with Crohn's disease in Japanese patients," Journal of Human Genetics, vol. 52, no. 7, pp. 575–583, 2007.

[27] M. J. Prescott, K. M. Dominy, M. Kubo et al., "Independent and population-specific association of risk variants at the IRGM locus with Crohn's disease," Human Molecular Genetics, vol. 19, no. 9, Article ID ddd041, pp. 1828–1839, 2010.
[35] S. Danese, C. de la Motte, and C. Fiocchi, "Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications," The American Journal of Gastroenterology, vol. 99, no. 5, pp. 938–945, 2004.

[36] C. E. Collins and D. S. Rampton, "Platelet dysfunction: a new dimension in inflammatory bowel disease," Gut, vol. 36, no. 1, pp. 5–8, 1995.

[37] W.-G. Dong, S.-P. Liu, H.-H. Zhu, H.-S. Luo, and J.-P. Yu, "Abnormal function of platelets and role of angina in patients with ulcerative colitis," World Journal of Gastroenterology, vol. 10, no. 4, pp. 606–609, 2004.

[38] H. Kayahan, M. Akarsu, M. A. Ozcan et al., "Reticulated platelet levels in patients with ulcerative colitis," International Journal of Colorectal Disease, vol. 22, no. 12, pp. 1429–1435, 2007.

[39] A. N. Kapsoritakis, M. I. Koukourakis, A. Sfiridakis et al., "Mean platelet volume: a useful marker of inflammatory bowel disease activity," The American Journal of Gastroenterology, vol. 96, no. 3, pp. 776–781, 2001.

[40] N. Zubcevic, R. Mesihovic, and S. Zubcevic, "Usefulness of laboratory data in estimation of Crohn's disease activity," Medicinski Arhiv, vol. 64, no. 1, pp. 33–36, 2010.

[41] A. Karnad and T. R. Poskitt, "The automated complete blood cell count. Use of the red blood cell volume distribution width and mean platelet volume in evaluating anemia and thrombocytopenia," Archives of Internal Medicine, vol. 145, no. 7, pp. 1270–1272, 1985.

[42] C. S. Song, D. I. Park, M. Y. Yoon et al., "Association between red cell distribution width and disease activity in patients with inflammatory bowel disease," Digestive Diseases and Sciences, vol. 57, no. 4, pp. 1033–1038, 2012.

[43] P. Oustamanolakis, I. E. Koutroubakis, I. Messaritakis, G. Kefalogiannis, M. Niniraki, and E. A. Kouroulasm, "Measurement of reticulocyte and red blood cell indices in the evaluation of anemia in inflammatory bowel disease," Journal of Crohn's and Colitis, vol. 5, no. 4, pp. 295–300, 2011.

[44] M. K. Fagerhol, I. Dale, and T. Andersson, "A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells," Bulletin European de Physiopathologie Respiratoire, vol. 16, suppl., pp. 273–282, 1980.

[45] A. G. Roseth, M. K. Fagerhol, E. Aadland, and H. Schjonsby, "Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study," Scandinavian Journal of Gastroenterology, vol. 27, no. 9, pp. 793–798, 1992.

[46] L. A. Smith and D. R. Gaya, "Utility of faecal calprotectin analysis in adult inflammatory bowel disease," World Journal of Gastroenterology, vol. 18, no. 46, pp. 6782–6789, 2012.

[47] J. Tibble, K. Teahon, B. Thjodleifsson et al., "A simple method for assessing intestinal inflammation in Crohn's disease," Gut, vol. 47, no. 4, pp. 506–513, 2000.

[48] A. M. Schepfer, M. Trummel, P. Seeholzer, B. Seibold-Schmid, and F. Seibold, "Discriminating IBIS from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBIS antibodies," Inflammatory Bowel Diseases, vol. 14, no. 1, pp. 32–39, 2008.

[49] A. C. von Roon, L. Karamountzos, S. Purkayastha et al., "Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy," The American Journal of Gastroenterology, vol. 102, no. 4, pp. 803–813, 2007.

[50] P. F. van Rheenen, E. Van de Vijver, and V. Fidler, "Facial calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis," British Medical Journal, vol. 341, Article ID c3369, 2010.

[51] T. Sipponen, E. Savilahti, K.-L. Kolho, H. Nuutinen, U. Turunen, and M. Färkkilä, "Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings," Inflammatory Bowel Diseases, vol. 14, no. 1, pp. 40–46, 2008.

[52] P. Ricanek, S. Brackmann, G. Perminow et al., "Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers," Scandinavian Journal of Gastroenterology, vol. 46, no. 9, pp. 1081–1091, 2011.

[53] T. Sipponen, C.-G. A. Björksten, M. Färkkilä, H. Nuutinen, E. Savilahti, and K.-L. Kolho, "Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment," Scandinavian Journal of Gastroenterology, vol. 45, no. 3, pp. 325–331, 2010.

[54] T. Sipponen, E. Savilahti, P. Kärkkäinen et al., "Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease," Inflammatory Bowel Diseases, vol. 14, no. 10, pp. 1392–1398, 2008.

[55] A. G. Roseth, E. Aadland, and K. Grzyb, "Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease," Scandinavian Journal of Gastroenterology, vol. 39, no. 10, pp. 1017–1020, 2004.

[56] R. Mao, Y. L. Xiao, X. Gao et al., "Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies," Inflammatory Bowel Diseases, vol. 18, no. 10, pp. 1894–1899, 2012.

[57] R. Shaoul, M. Sladek, D. Turner et al., "Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn's disease," Inflammatory Bowel Diseases, vol. 18, no. 8, pp. 1493–1497, 2012.

[58] A. Hämäläinen, T. Sipponen, and K.-L. Kolho, "Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels," World Journal of Gastroenterology, vol. 17, no. 47, pp. 5166–5171, 2011.

[59] A. Koulaouzidis, S. Douglas, M. A. Rogers, I. D. Arnott, and J. N. Plevris, "Fecal calprotectin: a selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy," Scandinavian Journal of Gastroenterology, vol. 46, no. 5, pp. 561–566, 2011.

[60] E. Burri, M. Manz, P. Schroeder et al., "Diagnostic yield of endoscopy in patients with abdominal complaints: incremental value of faecal calprotectin on guidelines of appropriateness," BMC Gastroenterology, vol. 14, article 57, 2014.

[61] N. Waugh, E. Cummins, P. Royle et al., "Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation," Health Technology Assessment, vol. 17, no. 55, pp. 1–211, 2013.

[62] NICE, "Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel," in NICE Diagnostics Guidance II, pp. 1–58, 2013.

[63] S. Baveye, E. Elass, J. Mazurier, G. Spik, and D. Legrand, "Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process," Clinical Chemistry and Laboratory Medicine, vol. 37, no. 3, pp. 281–286, 1999.

[64] R. D. Baynes and W. R. Bezwoda, "Lactoferrin and the inflammatory response," Advances in Experimental Medicine and Biology, vol. 357, pp. 133–141, 1994.

[65] S. V. Kane, W. J. Sandborn, P. A. Rufo et al., "Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation," The American Journal of Gastroenterology, vol. 98, no. 6, pp. 1309–1314, 2003.
D. Desai, W. A. Faubion, and W. J. Sandborn, “Review article: biological activity markers in inflammatory bowel disease,” *Alimentary Pharmacology and Therapeutics*, vol. 25, no. 3, pp. 247–255, 2007.

M. Joishy, I. Davies, M. Ahmed et al., “Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease,” *Journal of Pediatric Gastroenterology and Nutrition*, vol. 48, no. 1, pp. 48–54, 2009.

K. Sugi, O. Saitoh, I. Hirata, and K. Katsu, “Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins,” *The American Journal of Gastroenterology*, vol. 91, pp. 927–934, 1996.

J. Langhorst, S. Elsenbruch, J. Koelzer, A. Rueffer, A. Michalsen, and G. J. Dobos, “Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices,” *The American Journal of Gastroenterology*, vol. 103, no. 1, pp. 162–169, 2008.

T. Kaisser, J. Langhorst, H. Wittkowsky et al., “Fecal s100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome,” *Gut*, vol. 56, no. 12, pp. 1706–1713, 2007.

D. Foell, T. Kucharzik, M. Kraft et al., “Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease,” *Gut*, vol. 52, no. 6, pp. 847–853, 2003.

S. Nancey, A. Perret-Liaudet, D. Moussata et al., “Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases,” *Inflammatory Bowel Diseases*, vol. 19, no. 5, pp. 1043–1052, 2013.

N. Husain, K. Tokoro, J. M. Popov, S. J. Naides, M. J. Kwasy, and A. L. Buchman, “Neopterin concentration as an index of disease activity in Crohn’s disease and ulcerative colitis,” *Journal of Clinical Gastroenterology*, vol. 47, no. 3, pp. 246–251, 2013.

T. Tomankova, M. Petrek, J. Gallo, and E. Kriegerova, “MicroRNAs: emerging regulators of immune-mediated diseases,” *Scandinavian Journal of Immunology*, vol. 75, no. 2, pp. 129–141, 2012.

A. C. Manolakis, A. N. Kaporsitakis, E. K. Tiaka, and S. P. Potamianos, “Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease,” *Digestive Diseases and Sciences*, vol. 56, no. 6, pp. 1601–1611, 2011.

S. Nancey, A. Perret-Liaudet, D. Moussata et al., “Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases,” *Inflammatory Bowel Diseases*, vol. 19, no. 5, pp. 1043–1052, 2013.

N. Husain, K. Tokoro, J. M. Popov, S. J. Naides, M. J. Kwasy, and A. L. Buchman, “Neopterin concentration as an index of disease activity in Crohn’s disease and ulcerative colitis,” *Journal of Clinical Gastroenterology*, vol. 47, no. 3, pp. 246–251, 2013.

T. Tomankova, M. Petrek, J. Gallo, and E. Kriegerova, “MicroRNAs: emerging regulators of immune-mediated diseases,” *Scandinavian Journal of Immunology*, vol. 75, no. 2, pp. 129–141, 2012.

A. C. Manolakis, A. N. Kaporsitakis, E. K. Tiaka, and S. P. Potamianos, “Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease,” *Digestive Diseases and Sciences*, vol. 56, no. 6, pp. 1601–1611, 2011.

S. Nancey, A. Perret-Liaudet, D. Moussata et al., “Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases,” *Inflammatory Bowel Diseases*, vol. 19, no. 5, pp. 1043–1052, 2013.

N. Husain, K. Tokoro, J. M. Popov, S. J. Naides, M. J. Kwasy, and A. L. Buchman, “Neopterin concentration as an index of disease activity in Crohn’s disease and ulcerative colitis,” *Journal of Clinical Gastroenterology*, vol. 47, no. 3, pp. 246–251, 2013.

T. Tomankova, M. Petrek, J. Gallo, and E. Kriegerova, “MicroRNAs: emerging regulators of immune-mediated diseases,” *Scandinavian Journal of Immunology*, vol. 75, no. 2, pp. 129–141, 2012.

S. R. Dalal and J. H. Kwon, “The role of microRNA in inflammatory bowel disease,” *Gastroenterology and Hepatology*, vol. 6, no. 11, pp. 714–722, 2010.

F. Wu, N. J. Guo, H. Tian et al., “Peripheral blood MicroRNAs distinguish active ulcerative colitis and Crohn’s disease,” *Inflammatory Bowel Diseases*, vol. 17, no. 1, pp. 241–250, 2011.

I. Maor, T. Rainis, A. Lanir, and A. Lavy, “Adenosine deaminase activity in patients with Crohn’s disease: distinction between active and nonactive disease,” *European Journal of Gastroenterology and Hepatology*, vol. 23, no. 7, pp. 598–602, 2011.

P. L. Lakatos, L. S. Kiss, K. Palatka et al., “Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn’s disease,” *Inflammatory Bowel Diseases*, vol. 17, no. 3, pp. 767–777, 2011.

S. Shinzaki, E. Kuroki, H. Iijima et al., “Lectin-based immunoaosay for aberrant IgG glycosylation as the biomarker for Crohn’s disease,” *Inflammatory Bowel Diseases*, vol. 19, no. 2, pp. 321–331, 2013.

G. Judmaier, P. Meyersbach, G. Weiss, H. Wachtler, and G. Reinegger, “The role of neopterin in assessing disease activity in Crohn’s disease: classification and regression trees,” *The American Journal of Gastroenterology*, vol. 88, no. 5, pp. 706–711, 1993.

C. Huber, J. R. Batchelor, and D. Fuchs, “Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma,” *The Journal of Experimental Medicine*, vol. 160, no. 1, pp. 310–316, 1984.

P. C. Prior Ch., R. Bollbach, and D. Fuchs, “Urinary neopterin, a marker of clinical activity in patients with Crohn’s disease,” *Clinica Chimica Acta*, vol. 155, no. 1, pp. 11–21, 1986.

M. Konecny, J. Ehrmann, J. Bartek, Z. Hermanova, and I. Krč, “The level of neopterin in blood serum as one of the possible prognostic markers of Crohn’s disease activity,” *Acta Universitatis Palackianae Olomucensis Facultatis Medicae*, vol. 140, pp. 47–48, 1996.

S. Nancey, A. Perret-Liaudet, D. Moussata et al., “Urinary neopterin is a valuable tool in monitoring Crohn’s disease activity,” *Inflammatory Bowel Diseases*, vol. 14, no. 11, pp. 1548–1554, 2008.

D. Niederwieser, D. Fuchs, and A. Hausen, “Neopterin as a new biochemical marker in the clinical assessment of ulcerative colitis,” *Immunobiology*, vol. 170, no. 4, pp. 320–326, 1985.
Disease Markers

[98] J.-M. Reimund, Y. Arondel, G. Esclan, G. Finck, R. Baumann, and B. Duclos, “Immune activation and nutritional status in adult Crohn’s disease patients,” Digestive and Liver Disease, vol. 37, no. 6, pp. 424–431, 2005.

[99] H. Li, K. Tago, K. Ito et al., “The cloning and nucleotide sequence of human ST2L cDNA,” Genomics, vol. 67, no. 3, pp. 284–290, 2000.

[100] D. Diaz-Jimenez, L. E. Nunez, C. J. Beltran et al., “Soluble ST2: a new and promising activity marker in ulcerative colitis,” World Journal of Gastroenterology, vol. 17, no. 17, pp. 2181–2190, 2011.

[101] N. Avdagic, A. Zaciragic, N. Babic et al., “Nitric oxide as a potential biomarker in inflammatory bowel disease,” Bosnian Journal of Basic Medical Sciences, vol. 13, no. 1, pp. 5–9, 2013.

[102] M. Malerba, B. Ragnoli, L. Buffoliet al., “Exhaled nitric oxide as a marker of lung involvement in Crohn’s disease,” International Journal of Im munopathology and Pharmacology, vol. 24, no. 4, pp. 1119–1124, 2011.

[103] Y. S. Jung, J. J. Park, S. W. Kim et al., “Correlation between soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) expression and endoscopic activity in inflammatory bowel diseases,” Digestive and Liver Disease, vol. 44, no. 11, pp. 897–903, 2012.

[104] F. Tavano, F. F. di Mola, A. Latiano et al., “Neuroimmune interactions in patients with inflammatory bowel diseases: disease activity and clinical behavior based on Substance P serum levels,” Journal of Crohn’s and Colitis, vol. 6, no. 5, pp. 563–570, 2012.

[105] D. Owczarek, A. Undas, J. H. Foley, M. E. Nesheim, K. Jablonski, and T. Mach, “Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD,” Journal of Crohn’s and Colitis, vol. 6, no. 1, pp. 13–20, 2012.

[106] A. Nakarai, J. Kato, S. Hiraoka et al., “Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test,” The American Journal of Gastroenterology, vol. 108, pp. 83–89, 2013.

[107] T. Aomatsu, H. Imaeda, K. Matsumoto et al., “Facal chitinate 3-like-1: a novel biomarker of disease activity in paediatric inflammatory bowel disease,” Alimentary Pharmacology and Therapeutics, vol. 34, no. 8, pp. 941–948, 2011.

[108] K. A. Oikonomou, A. N. Kapsoritakis, A. I. Kapsoritaki et al., “Angiogenin, angiopoietin-1, angiopoietin-2, and endostatin serum levels in inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 17, no. 4, pp. 963–970, 2011.

[109] M. A. Cierva, “Indoleamine 2,3 dioxygenase in intestinal disease,” Current Opinion in Gastroenterology, vol. 29, no. 2, pp. 146–152, 2013.

[110] R. Rismo, T. Olsen, G. Cui, I. Christiansen, J. Florholmen, and R. Goll, “Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis,” Scandinavian Journal of Gastroenterology, vol. 47, no. 5, pp. 538–547, 2012.

[111] A. Kathrani, S. Schmitz, S. L. Priestnall et al., “CD11c+ cells are significantly decreased in the duodenum, ileum and colon of dogs with inflammatory bowel disease,” Journal of Comparative Pathology, vol. 145, no. 4, pp. 359–366, 2011.

[112] F. Scaldaferr, C. Correale, A. Gasbarrini, and S. Danese, “Mucosal biomarkers in inflammatory bowel disease: key pathogenic players or disease predictors?” World Journal of Gastroenterology, vol. 16, no. 21, pp. 2616–2625, 2010.

[113] W.-B. Song, Y.-H. Iw, Z.-S. Zhang et al., “Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease,” World Journal of Gastroenterology, vol. 15, no. 31, pp. 3916–3919, 2009.

[114] C. J. Landers, O. Cohavy, R. Misra et al., “Selected loss of tolerance evidenced by Crohn’s disease-associated immune responses to auto- and microbial antigens,” Gastroenterology, vol. 123, no. 3, pp. 689–699, 2002.

[115] S. R. Targan, C. J. Landers, H. Yang et al., “Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease,” Gastroenterology, vol. 128, no. 7, pp. 2020–2028, 2005.

[116] G. W. Moran, C. O’Neill, P. Padfield, and J. T. McLaughlin, “Dipeptidyl peptidase-4 expression is reduced in Crohn’s disease,” Regulatory Peptides, vol. 177, no. 1–3, pp. 40–45, 2012.

[117] K. S. Nanda, A. S. Cheifetz, and A. C. Moss, “Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis,” The American Journal of Gastroenterology, vol. 108, quiz 48, pp. 40–47, 2013.

[118] E. Burri, C. Beglinger, and F. S. Lehmann, “Monitoring of therapy for inflammatory bowel disease,” Digestion, vol. 86, supplement 1, pp. 1–5, 2012.

[119] S. Ben-Horin, M. Yavzori, L. Katz et al., “The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful,” Gut, vol. 60, no. 1, pp. 41–48, 2011.

[120] Y. González-Lama, F. Bermejo, A. López-Sanromá et al., “Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients,” Alimentary Pharmacology and Therapeutics, vol. 34, no. 5, pp. 544–554, 2011.

[121] A. E. Gifford, A. H. Berg, C. Lahiff, A. S. Cheifetz, G. Horowitz, and A. C. Moss, “A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study,” The American Journal of Gastroenterology, vol. 108, pp. 249–255, 2013.

[122] U. Potocnik, I. Ferkolj, D. Glavač, and M. Dean, “Polymorphisms in multidrug resistance 1 (MDRI) gene are associated with refractory Crohn disease and ulcerative colitis,” Genes and Immunity, vol. 5, no. 7, pp. 530–539, 2004.

[123] F. Daniel, M.-A. Loriot, P. Seksik et al., “Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis,” Inflammatory Bowel Diseases, vol. 13, no. 1, pp. 19–23, 2007.

[124] T. Hlavaty, L. Peterik, L. Henckaerts et al., “Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn’s disease,” Alimentary Pharmacology and Therapeutics, vol. 22, no. 7, pp. 613–626, 2005.

[125] E. Czu, K.-H. Herzig, A. Szafiłska-�polańska et al., “Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease,” Scandinavian Journal of Gastroenterology, vol. 42, no. 10, pp. 1147–1150, 2007.

[126] J. Walkowiak, T. Banasiewicz, P. Krokowicz, R. Hansdorfer-Korzon, M. Drews, and K.-H. Herzig, “Fecal pyruvate kinase (M2-PK): a new predictor for inflammation and severity of pouchitis,” Scandinavian Journal of Gastroenterology, vol. 40, no. 12, pp. 1493–1494, 2005.

[127] G. McDowell, S. Gupta, M. Dellerba, T. Coppinger, R. D. Levy, and B. G. Keevil, “Plasma concentrations of tumour dimeric pyruvate kinase are increased in patients with chronic failure,” Annals of Clinical Biochemistry, vol. 41, no. 6, pp. 491–493, 2004.
Disease Markers

[128] R. Oehler, G. Weingartmann, N. Manhart et al., “Polytrauma induces increased expression of pyruvate kinase in neutrophils,” *Blood*, vol. 95, no. 3, pp. 1086–1092, 2000.

[129] P. D. Hardt, S. Mazurek, M. Toepfer et al., “Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer,” *British Journal of Cancer*, vol. 91, no. 5, pp. 980–984, 2004.

[130] G. Chung-Faye, B. Hayee, S. Maestranzi, N. Donaldson, I. Forgacs, and R. Sherwood, “Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation,” *Inflammatory Bowel Diseases*, vol. 13, no. 11, pp. 1374–1378, 2007.

[131] K. D. Taganov, M. P. Boldin, K.-J. Chang, and D. Baltimore, “NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 33, pp. 12481–12486, 2006.

[132] M. Fasseu, X. Tréton, C. Guichard et al., “Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease,” *PLoS ONE*, vol. 5, no. 10, Article ID e13160, 2010.

[133] K. Ludwig, M. Fassan, C. Mescoli et al., “PDCD4/miR-21 dysregulation in inflammatory bowel disease-associated carcinogenesis,” *Virchows Archiv*, vol. 462, no. 1, pp. 57–63, 2013.

[134] A. V. Olaru, F. M. Selaru, Y. Mori et al., “Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation,” *Inflammatory Bowel Diseases*, vol. 17, no. 1, pp. 221–231, 2011.

[135] C. W. Wu, S. S. M. Ng, Y. J. Dong et al., “Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps,” *Gut*, vol. 61, no. 5, pp. 739–745, 2012.

[136] C.-C. Chen, J. Pekow, V. Llado et al., “Chitinase 3-like-1 expression in colonic epithelial cells as a potentially novel marker for colitis-associated neoplasia,” *The American Journal of Pathology*, vol. 179, no. 3, pp. 1494–1503, 2011.